The people-first approach transforming eClinical processes
Pharmaceutical Technology
NOVEMBER 7, 2024
With the boom in eClinical solutions showing no signs of slowing, adding a “human at the center” perspective can help optimize data management
Thu.Nov 07, 2024
130 
Sarepta scraps a Duchenne drug as gene therapy sales rise
Bio Pharma Dive
NOVEMBER 7, 2024
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
Pharmaceutical Technology
NOVEMBER 7, 2024
The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.
Novo sheds kidney drug licensed for $1.3bn a year ago
pharmaphorum
NOVEMBER 7, 2024
Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.The Danish group bought rights to ocedurenone, an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA), from the Singapore biotech in October 2023 as a companion to its GLP-1-based therapies for reducing cardiovascular risk and kidney disease in people with diabetes and obesity.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Minister for Science champions partnerships with private clinical sector in UK
Pharmaceutical Technology
NOVEMBER 7, 2024
Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Bio Pharma Dive
NOVEMBER 7, 2024
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
New study to assess mpox vaccine in pregnant women and infants
Pharma Times
NOVEMBER 7, 2024
Trial to evaluate safety and efficacy of MVA-BN vaccine
Driving Improvements at Sites Through a Culture of Connectedness
ACRP blog
NOVEMBER 7, 2024
The wisdom of generations before ours says that “a rising tide lifts all boats,” to which modern clinical research veterans might add, “building a sense of community among scattered clinical trial sites can help to keep all of the stakeholders in medical research afloat in trying times.” Addressing a framework for assessing the overall robustness at sites in terms of compliance, business, financial, regulatory, and clinical dimensions is the goal of an ACRP 2025 preconference half-day workshop
Elsevier backs Pistoia Alliance for AI in drug discovery
Pharma Times
NOVEMBER 7, 2024
New initiatives to tackle AI-related challenges in life sciences
Santen, Arctic Vision sign deal for ARVN001 to treat UME
Pharmaceutical Technology
NOVEMBER 7, 2024
Santen Pharmaceutical and Arctic Vision have signed a commercial collaboration agreement for the ARVN001to treat uveitic macular oedema.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Sarepta pulls plug on Duchenne exon-skipping drug
pharmaphorum
NOVEMBER 7, 2024
Sarepta has halted development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy therapy Exondys 51.
Q3 2024 update: COVID-19 related private equity activity in the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $7.5m, according to GlobalData's Deals Database.
Webinar recap: Boosting recruitment and retention with SDOH data
pharmaphorum
NOVEMBER 7, 2024
Discover the key takeaways from a webinar focused on boosting recruitment and retention through Social Determinants of Health (SDOH) data. Learn how incorporating SDOH data can enhance your recruitment and retention strategies.
Q3 2024 update: artificial intelligence related private equity activity in the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were three private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.
Avid Bioservices to go private in $1.1bn private equity deal
pharmaphorum
NOVEMBER 7, 2024
Nasdaq-listed CDMO Avid Bioservices has agreed a $1.
Private equity deals in pharmaceutical in Canada remained flat in Q3 2024
Pharmaceutical Technology
NOVEMBER 7, 2024
In Canada pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.
Blueprint's mastocytosis drug Ayvakit cleared for NHS use
pharmaphorum
NOVEMBER 7, 2024
NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis
Leading sales and marketing intent data, database and data enrichment providers and technology solutions for the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
Discover the top sales and marketing intelligence providers for the pharmaceutical industry, offering predictive insights and data enrichment to drive growth.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist
Outsourcing Pharma
NOVEMBER 7, 2024
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Vidac secures funding to advance skin cancer trials of novel ointment
Pharmaceutical Technology
NOVEMBER 7, 2024
Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.
Metrics for the UK’s VPAG: A work in progress
pharmaphorum
NOVEMBER 7, 2024
Discover the latest metrics and updates on the UK's VPAG (Voluntary scheme for branded medicines Pricing, Access and Growth) from NICE (National Institute for Health and Care Excellence). Stay informed on this work in progress.
GHO and Ampersand Capital to acquire Avid Bioservices
Pharmaceutical Technology
NOVEMBER 7, 2024
Funds managed by GHO Capital Partners and Ampersand Capital Partners have signed a definitive agreement to acquire Avid Bioservices.
More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce
Fierce Pharma
NOVEMBER 7, 2024
After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring. | After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring, cutting the autoimmune disease biotech's workforce for a second time in less than a year.
Q3 2024 update: ecommerce related M&A activity in the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were eight M&A deals announced in Q3 2024, worth a total value of $1.3bn, according to GlobalData's Deals Database.
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Fierce Pharma
NOVEMBER 7, 2024
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its bread-and-butter antirival franchise with an eye on the potential of its long-acting | Gilead's CAR-T therapies Yescarta and Tecartus have stayed relatively flat all year with its Yescarta facing a 1% decline over the third quarter due to competition.
Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist
BioPharma Reporter
NOVEMBER 7, 2024
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales
Fierce Pharma
NOVEMBER 7, 2024
An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the gene therapy. | An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy Elevidys has sparked a new surge in sales. The gene therapy's $181 million sales in the third quarter beat analysts' expectations as it made a 48% sequential leap.
Senhwa Biosciences starts trial of silmitasertib in children with difficult to treat cancers
Outsourcing Pharma
NOVEMBER 7, 2024
The Taiwanese biotech has launched a phase 1/2 trial to test its small molecule cancer therapy in children and young adults with relapsed or treatment resistant tumors.
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Fierce Pharma
NOVEMBER 7, 2024
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. But the Massachusetts biotech's RSV shot fell way short of expectations.
Tips For Starting A Healthcare Podcast in Pharma
Pharma Marketing Network
NOVEMBER 7, 2024
Healthcare podcasts are revolutionizing the way information is shared in the pharmaceutical industry. As a pharma marketing executive, launching a podcast can elevate your brand, engage healthcare professionals (HCPs), and establish your company as a thought leader. But where do you start? Don’t worry—this guide will walk you through everything you need to know about creating an impactful healthcare podcast.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Let's personalize your content